Medexus Pharmaceuticals Inc. (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) said it has renewed and expanded its distribution agreement for NYDA, a market-leading treatment for head lice, through to September 26, 2026.
The agreement with G. Pohl-Boskamp GmbH & Co KG provides the company with exclusive Canadian distribution rights for NYDA and includes a commitment related to bringing new and innovative solutions to the Canadian market. The initial agreement with Pohl-Boskamp was signed in 2011 and the first extension was announced in June 2015.
READ: Medexus Pharmaceuticals submits application to list on Nasdaq
In a statement, Richard Labelle, vice president Allergy, Pediatric and OTC Portfolios at Medexus, commented: “The renewal and expansion of the agreement is the result of the solid relationship established over the years and based on the success achieved by NYDA since its introduction in the Canadian market in 2012.
"Medexus is excited to extend this partnership that has resulted in a market leader in the category. We are currently working towards providing patients with new and improved offerings of this treatment.”
Medexus is a leading specialty pharmaceutical company focused on the therapeutic areas of auto-immune disease, hematology and allergy.
The company’s leading products are: Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative allergy medication with a unique mode of action.
Contact the author at jon.hopkins@proactiveinvestors.com